Johnson & Johnson $JNJ Position Reduced by Intrua Financial LLC

Intrua Financial LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 14.8% in the first quarter, HoldingsChannel.com reports. The firm owned 12,294 shares of the company’s stock after selling 2,133 shares during the quarter. Intrua Financial LLC’s holdings in Johnson & Johnson were worth $3,005,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. EWA LLC raised its stake in shares of Johnson & Johnson by 31.6% in the 1st quarter. EWA LLC now owns 4,235 shares of the company’s stock worth $1,035,000 after buying an additional 1,018 shares in the last quarter. Simmons Bank boosted its stake in Johnson & Johnson by 2.1% during the first quarter. Simmons Bank now owns 34,243 shares of the company’s stock valued at $8,370,000 after buying an additional 704 shares in the last quarter. Fairway Wealth LLC raised its position in Johnson & Johnson by 2,916.7% in the first quarter. Fairway Wealth LLC now owns 3,439 shares of the company’s stock worth $841,000 after acquiring an additional 3,325 shares in the last quarter. Investment Planning Advisors Inc. lifted its holdings in Johnson & Johnson by 27.2% in the 1st quarter. Investment Planning Advisors Inc. now owns 1,545 shares of the company’s stock valued at $378,000 after acquiring an additional 330 shares during the last quarter. Finally, Next Level Private LLC grew its stake in shares of Johnson & Johnson by 5.9% in the 1st quarter. Next Level Private LLC now owns 4,768 shares of the company’s stock worth $1,166,000 after purchasing an additional 264 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on JNJ shares. Guggenheim raised their target price on shares of Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Johnson Rice set a $270.00 target price on Johnson & Johnson in a report on Friday, June 26th. TD Cowen assumed coverage on Johnson & Johnson in a research report on Wednesday, April 8th. They issued a “buy” rating and a $250.00 price target for the company. Stifel Nicolaus lifted their price target on Johnson & Johnson from $220.00 to $250.00 and gave the stock a “hold” rating in a research note on Wednesday, April 15th. Finally, Sanford C. Bernstein boosted their price objective on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $256.70.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $262.52 on Friday. The company’s fifty day moving average is $232.98 and its two-hundred day moving average is $231.04. The company has a market cap of $631.93 billion, a P/E ratio of 30.35, a price-to-earnings-growth ratio of 2.49 and a beta of 0.24. Johnson & Johnson has a 12-month low of $154.21 and a 12-month high of $263.10. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.Johnson & Johnson’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the firm posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were paid a dividend of $1.34 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 61.97%.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation catheter platform in Europe, expanding access for electrophysiologists and adding another potential growth driver for its med-tech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: The company is drawing attention as a top dividend and defensive healthcare name, with articles highlighting its reliable payout, global healthcare reach, and appeal to income-focused investors. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street’s Bullish Views?
• Positive Sentiment: Johnson & Johnson is being favored for long-term growth because management is emphasizing cancer and neuroscience, while expanding its oncology pipeline through regulatory progress in Europe and the planned Firefly Bio acquisition. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several articles compare J&J with other dividend and healthcare stocks or discuss passive-income strategies, but these are more general investor-interest pieces than direct company-specific catalysts. 3 Dividend Stocks to Buy Hand Over Fist in July
• Neutral Sentiment: Analysts are watching J&J’s Q2 Innovative Medicine business closely, with Stelara biosimilar pressure potentially offset by growth from newer drugs and blockbusters ahead of earnings. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Negative Sentiment: One near-term risk remains biosimilar competition for Stelara, which could weigh on Innovative Medicine growth if newer products do not fully offset the pressure. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the transaction, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.